Growth hormone and Prader-Willi syndrome: What we know and have yet to learn

Endocrinologist

Volumn 13, Issue 2, 2003, Pages 106-111

  Carrel, Aaron L ^a,b   Allen, David B ^a  

^a University of Wisconsin Children's Hospital   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

BEHAVIOR DISORDER; BODY COMPOSITION; BODY HEIGHT; CARBOHYDRATE METABOLISM; CARDIOPULMONARY INSUFFICIENCY; DISEASE ASSOCIATION; ENERGY EXPENDITURE; GROWTH HORMONE DEFICIENCY; HUMAN; HYPOGONADISM; HYPOTHALAMUS DISEASE; LEAN BODY WEIGHT; LIPID METABOLISM; MORBIDITY; MUSCLE HYPOTONIA; MUSCLE MASS; MUSCLE STRENGTH; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOPOROSIS; PHYSICAL ACTIVITY; PRADER WILLI SYNDROME; RESPIRATORY TRACT DISEASE; REVIEW;

EID: 0037948919     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ten.0000076212.95014.82     Document Type: Review

References (23)

1. Prader A, Labhart A, Willi H. Ein syndrom von adipositas, kleinwuchs, kryptorchismus und oligophrenie. Schweiz Med Wochenschr 1956; 86: 1260-1.
2. Butler MG, Thompson T. Prader-Willi syndrome: clinical and genetic findings. Endocrinologist, 2000; (10 suppl 1): 3S-16S.
3. Ritzen EM, Bolme P, Hall K. Endocrine physiology and therapy in Prader-Willi syndrome. In: Cassidy SB, ed. Prader-Willi Syndrome and Other 15q Deletion Disorders. Berlin: Springer-Verlag; 1992:153-69.
4. Cassidy SB. Prader-Willi syndrome. J Med Genet 1997; 34: 917-23.
5. Brambilla P, Bosio L, ManzoniPeculiar body composition in patients with Prader-Labhart-Willi syndrome. Am J Clin Nutr 1997; 65: 1369-74.
6. Lindgren AC and Ritzen EM, Five years of growth hormone treatment in children with Prader-Willi syndrome. Swedish National Growth Hormone Advisory Group. Acta Paediatrica 1999; 88: 109-11.
7. Eiholzer U, Bachmann S. Is there growth hormone deficiency in Prader-Willi syndrome? Six arguments to support the presence of hypothalamic growth hormone deficiency in PWS. Horm Res 2000; 53(supp 3): 44-52.
8. Davies PS, Growth hormone therapy in Prader-Willi syndrome. Inter J Obesity 2001; 25: 2-7.
9. Burman P, Ritzen EM, and Lindgren AC, Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocrine Reviews, 2001; 22: 787-99.
10. Carrel AL, Myers SE, Whitman BY, Allen DB. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: a controlled study. J Pediatr 1999; 134: 2152-221.
11. Carrel AL, Myers SE, Whitman BY, Allen DB. Sustained benefits of growth hormone in children with Prader-Willi syndrome are dose-dependent. J Ped Endo Metab 2001; 14: 1096-105.
12. Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term growth hormone therapy in Prader-Willi syndrome: A 4-year study. J Clin Endo Metab 2002; 87: 1581-5.
13. Raben M, Hollenberg CH. Effect of growth hormone on plasma fatty acids. J Clin Invest 1959, 38: 484-8.
14. Dieguez C, Page MD, Scanlon MF. Growth hormone neuroregulation and its alterations in disease states. Clin Endocrinol (Oxf) 1988; 28: 109-43.
15. Dieguez C, Casanueva FF. Influence of metabolic substrates and obesity on growth hormone secretion. Trends Endocrinol Metab 1995; 6: 55-59.
16. van Mil EAG, Westerterp KR, Gerver WJ, et al. Energy expenditure at rest and during sleep in children with Prader-Willi syndrome is explained by body composition. Am J Clin Nutr 2000; 71: 752-6.
17. Lustig RL. Hypothalamic obesity: The sixth cranial endocrinopathy. Endocrinologist 2002; 12: 210-7.
18. Lindgren AC, Hagenas L, Ritzen EM. Growth hormone treatment of children with Prader-Willi syndrome: effects on glucose and insulin homeostasis. Horm Res 1999, 51; 4: 157-61.
19. Eiholzer U, l'Allemand D. Growth hormone normalizes height, prediction of final height, hand length in children with Prader-Willi syndrome after 4 years of therapy. Horm Res 2000; 53; 4: 185-92.
20. Richelson B. Actions of growth hormone in adipose tissue. Horm Res 1997; 48; 5: 105-10.
21. Goldstone AP, Thomas EL, Brynes AE, et al. Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution. J Clin Endo Metab 2001, 86; 9: 4330-8.
22. l'Allemand D, Eiholzer U, Schlumpf M, et al. Cardiovascular risk factors improve during 3 years of growth hormone therapy in Prader-Willi syndrome. Eur J Ped 2000; 159: 835-42.
23. Whitman BY, Myers SE, Carrel AL, Allen DB. The behavioral impact of growth hormone treatment for children with Prader-Willi syndrome: A 2-year controlled study. Pediatrics 2002; 109: 35.